Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Manfredi

Showing results (111-120 of 114) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 114 results.
The American Journal of Psychiatry|December 22, 2021
REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind TrialMaurizio Fava, Stephen Stahl, Luca Pani, et al.
The Journal of Clinical Psychiatry|June 25, 2024
Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled TrialMaurizio Fava, Stephen M Stahl, Luca Pani, et al.
Frontiers in Research Metrics and Analytics|December 26, 2024
Catalyzing sustainable development: insights from the international workshop on STI policies and innovation systems in Central AmericaJorge A Huete-Pérez, Alma Cristal Hernández-Mondragón, Douglas S Massey, et al.
Pharmacological Research|December 31, 2025
Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and Type 2 Diabetes via 5-HT2B receptor-dependent mechanismsMartina Colognesi, Daniela Gabbia, Anna Signor, et al.
Pageof 12

Showing results (111-120 of 114) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 114 results.
The American Journal of Psychiatry|December 22, 2021
REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind TrialMaurizio Fava, Stephen Stahl, Luca Pani, et al.
The Journal of Clinical Psychiatry|June 25, 2024
Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled TrialMaurizio Fava, Stephen M Stahl, Luca Pani, et al.
Frontiers in Research Metrics and Analytics|December 26, 2024
Catalyzing sustainable development: insights from the international workshop on STI policies and innovation systems in Central AmericaJorge A Huete-Pérez, Alma Cristal Hernández-Mondragón, Douglas S Massey, et al.
Pharmacological Research|December 31, 2025
Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and Type 2 Diabetes via 5-HT2B receptor-dependent mechanismsMartina Colognesi, Daniela Gabbia, Anna Signor, et al.
Pageof 12